Advertisement
Organisation › Details
Sangamo Therapeutics Inc. (Nasdaq: SGMO)
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in Phase 2 clinical trials for evaluation of safety in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF™) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN™) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. A portion of Sangamo's research in plant agriculture is supported by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology. Sangamo has also established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. *
Start | 2018-07-23 renamed before | |
Group | Sangamo (Group) | |
Predecessor | Sangamo BioSciences Inc. (Nasdaq: SGMO) | |
Industry | BIOTECH | |
Person | Macrae, Sandy (Sangamo 201807 CEO) | |
Person 2 | Lee, Sung (MorphoSys 202102–202303 CFO before Sangamo + Gilead Sciences LEFT 3/23) | |
Street | 501 Canal Boulevard | |
City | 94804 Richmond, CA | |
Tel | +1-510-970-6000 | |
Address record changed: 2024-08-08 | ||
Basic data | Employees | D: 101 to 500 (2023-12-31) |
Currency | USD | |
Annual sales | 176,232,000 (revenues, annual, consolidated (2023) 2023-12-31) | |
Profit | -257,831,000 (2023-12-31) | |
Cash | 80,992,000 (2023-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-08-14 |
Advertisement
More documents for Sangamo (Group)
- [1] Sangamo Therapeutics, Inc.. (8/6/24). "Press Release: Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases". Richmond, CA....
- [2] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
- [3] Mogrify Ltd.. (4/21/20). "Press Release: Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-derived Regulatory T Cells". Cambridge & Brisbane, CA....
- [4] Sangamo Therapeutics, Inc.. (11/19/19). "Press Release: Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation". Brisbane, CA....
- [5] Sangamo Therapeutics, Inc.. (11/18/19). "Press Release: Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference". Brisbane, CA....
- [6] Sangamo Therapeutics, Inc.. (11/1/19). "Press Release: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer". Brisbane, CA....
- [7] Sangamo Therapeutics, Inc.. (7/31/19). "Press Release: Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel". Brisbane, CA....
- [8] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Announces Agreement Securing Access To Large-scale, Commercial-grade Manufacturing Capacity at Brammer Bio". Brisbane, CA....
- [9] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy". Brisbane, CA & New York, NY....
- [10] Sangamo Therapeutics, Inc.. (4/2/19). "Press Release: Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data". Brisbane, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top